{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T07:03:32Z","timestamp":1780297412373,"version":"3.54.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.trim.2026.102385","type":"journal-article","created":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T11:20:22Z","timestamp":1775388022000},"page":"102385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The effect of SGLT2 inhibition on immune cells and transplant rejection\/failure: A drug-targeted mendelian randomization study"],"prefix":"10.1016","volume":"96","author":[{"given":"Hanyu","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qidan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhe","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trim.2026.102385_bb0005","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.trim.2026.102385_bb0010","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"LANCET"},{"key":"10.1016\/j.trim.2026.102385_bb0015","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trim.2026.102385_bb0020","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41581-022-00535-6","article-title":"Kidney and heart failure outcomes associated with SGLT2 inhibitor use","volume":"18","author":"van der Aart-van","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.trim.2026.102385_bb0025","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1097\/TP.0000000000004228","article-title":"The efficacy and safety of SGLT2 inhibitor in diabetic kidney transplant recipients","volume":"106","author":"Lim","year":"2022","journal-title":"TRANSPLANTATION"},{"key":"10.1016\/j.trim.2026.102385_bb0035","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.70233","article-title":"Potential role of SGLT-2 inhibitors in improving allograft function and reducing rejection in kidney transplantation","volume":"39","author":"Demir","year":"2025","journal-title":"Clin. Transplant."},{"key":"10.1016\/j.trim.2026.102385_bb0040","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.2215\/CJN.0000000000000221","article-title":"Will SGLT2 inhibitors be effective and safe in patients with severe CKD, dialysis, or kidney transplantation","volume":"18","author":"Heerspink","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.trim.2026.102385_bb0045","doi-asserted-by":"crossref","first-page":"1589341","DOI":"10.3389\/fimmu.2025.1589341","article-title":"SGLT2 inhibitors in autoimmune diseases: emerging therapeutic potential and clinical challenges","volume":"16","author":"Luo","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trim.2026.102385_bb0050","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.cmet.2023.05.001","article-title":"Canagliflozin impairs t cell effector function via metabolic suppression in autoimmunity","volume":"35","author":"Jenkins","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.trim.2026.102385_bb0055","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/bjh.18293","article-title":"Empagliflozin modulates CD4(+) t-cell differentiation via metabolic reprogramming in immune thrombocytopenia","volume":"198","author":"Qin","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.trim.2026.102385_bb0060","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s12933-023-02019-8","article-title":"SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a mendelian randomization study","volume":"22","author":"Li","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.trim.2026.102385_bb0065","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jama.2021.18236","article-title":"Strengthening the reporting of observational studies in epidemiology using mendelian randomization: the STROBE-MR statement","volume":"326","author":"Skrivankova","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.trim.2026.102385_bb0070","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jacc.2022.05.041","article-title":"Mendelian randomization study of PCSK9 and HMG-CoA reductase inhibition and cognitive function","volume":"80","author":"Rosoff","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.trim.2026.102385_bb0075","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.aaz1776","article-title":"Atlas of genetic regulatory effects across human tissues","volume":"369","author":"The GTEx Consortium","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.trim.2026.102385_bb0080","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s41588-021-00913-z","article-title":"Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression","volume":"53","author":"Vosa","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.trim.2026.102385_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177957","article-title":"The paradox of SGLT2 inhibitors in heart failure: caution with drug target mendelian randomization","volume":"1003","author":"Huang","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.trim.2026.102385_bb0090","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1161\/STROKEAHA.122.040598","article-title":"Anti-epileptic drug target perturbation and intracranial aneurysm risk: mendelian randomization and colocalization study","volume":"54","author":"Bakker","year":"2023","journal-title":"STROKE"},{"key":"10.1016\/j.trim.2026.102385_bb0095","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.trim.2026.102385_bb0100","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/03602532.2025.2462527","article-title":"Scaling factors to inform in vitro-in vivo extrapolation from preclinical and livestock animals: state of the field and recommendations for development of missing data","volume":"57","author":"Zimmer","year":"2025","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.trim.2026.102385_bb0105","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41588-020-0684-4","article-title":"Complex genetic signatures in immune cells underlie autoimmunity and inform therapy","volume":"52","author":"Orru","year":"2020","journal-title":"Nat. Genet."},{"key":"10.1016\/j.trim.2026.102385_bb0110","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41586-022-05473-8","article-title":"Finngen provides genetic insights from a well-phenotyped isolated population","volume":"613","author":"Kurki","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.trim.2026.102385_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009922","article-title":"Combining the strengths of inverse-variance weighting and egger regression in mendelian randomization using a mixture of regressions model","volume":"17","author":"Lin","year":"2021","journal-title":"PLoS Genet."},{"key":"10.1016\/j.trim.2026.102385_bb0120","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1037\/1082-989X.7.1.83","article-title":"A comparison of methods to test mediation and other intervening variable effects","volume":"7","author":"MacKinnon","year":"2002","journal-title":"Psychol. Methods"},{"key":"10.1016\/j.trim.2026.102385_bb0125","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ije\/dyv080","article-title":"Mendelian randomization with invalid instruments: effect estimation and bias detection through egger regression","volume":"44","author":"Bowden","year":"2015","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.trim.2026.102385_bb0130","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","article-title":"Detection of widespread horizontal pleiotropy in causal relationships inferred from mendelian randomization between complex traits and diseases","volume":"50","author":"Verbanck","year":"2018","journal-title":"Nat. Genet."},{"key":"10.1016\/j.trim.2026.102385_bb0135","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.transproceed.2024.12.009","article-title":"Use of SGLT2i in non-diabetic kidney transplant recipients","volume":"57","author":"Quilis","year":"2025","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.trim.2026.102385_bb0140","doi-asserted-by":"crossref","first-page":"12879","DOI":"10.3389\/ti.2024.12879","article-title":"SGLT2 inhibitors correct fluid overload in adult kidney transplant recipients-a prospective observational study","volume":"37","author":"Schork","year":"2024","journal-title":"Transpl. Int."},{"key":"10.1016\/j.trim.2026.102385_bb0145","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00125-022-05815-1","article-title":"Ketones: the double-edged sword of SGLT2 inhibitors?","volume":"66","author":"Lupsa","year":"2023","journal-title":"DIABETOLOGIA"},{"key":"10.1016\/j.trim.2026.102385_bb0150","doi-asserted-by":"crossref","first-page":"10043","DOI":"10.1038\/s41467-024-54171-8","article-title":"The outcomes of SGLT-2 inhibitor utilization in diabetic kidney transplant recipients","volume":"15","author":"Sheu","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.trim.2026.102385_bb0155","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1097\/TP.0000000000005496","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists in kidney transplantation: a systematic review and meta-analysis","volume":"110","author":"Lee","year":"2026","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2026.102385_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.102520","article-title":"Diabetes therapy with SGLT2i after heart transplant: a multi-institutional analysis","volume":"13","author":"Brinker","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.trim.2026.102385_bb0165","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/joim.20077","article-title":"Effects of SGLT2 inhibitors on transplant survival and key clinical outcomes in heart transplant recipients with diabetes","volume":"297","author":"Yen","year":"2025","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.trim.2026.102385_bb0170","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/15269248231189880","article-title":"Safety and efficacy of sodium-glucose cotransporter-2 inhibitors in solid organ transplant recipients","volume":"33","author":"Sweiss","year":"2023","journal-title":"Prog. Transplant."},{"key":"10.1016\/j.trim.2026.102385_bb0175","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.70104","article-title":"Safety and tolerability of SGLT-2 inhibitors following lung transplantation","volume":"39","author":"Wilcox","year":"2025","journal-title":"Clin. Transplant."},{"key":"10.1016\/j.trim.2026.102385_bb0180","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1038\/s41591-024-03087-3","article-title":"Cell-free DNA for the detection of kidney allograft rejection","volume":"30","author":"Aubert","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.trim.2026.102385_bb0185","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1007\/s11255-023-03645-7","article-title":"The results of SGLT-2 inhibitors use in kidney transplantation: 1-year experiences from two centers","volume":"55","author":"Demir","year":"2023","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.trim.2026.102385_bb0190","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.cmet.2024.08.005","article-title":"SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8(+) t?Cell activation","volume":"36","author":"Liu","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.trim.2026.102385_bb0195","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.tem.2023.03.006","article-title":"The relationship between CD4(+) t cell glycolysis and their functions","volume":"34","author":"Liu","year":"2023","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.trim.2026.102385_bb0200","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.it.2017.03.001","article-title":"Macrophage immunometabolism: where are we (going)?","volume":"38","author":"Van den Bossche","year":"2017","journal-title":"Trends Immunol."},{"key":"10.1016\/j.trim.2026.102385_bb0205","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nm.3804","article-title":"The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease","volume":"21","author":"Youm","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.trim.2026.102385_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2025.103949","article-title":"\u0392-hydroxybutyrate ameliorates lipopolysaccharide-induced liver injury through \u03b2-hydroxybutyrylation of the SOD2 protein in mice","volume":"88","author":"Bai","year":"2025","journal-title":"Redox Biol."},{"key":"10.1016\/j.trim.2026.102385_bb0215","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41423-025-01281-y","article-title":"The intrinsic expression of NLRP3 in th17 cells promotes their protumor activity and conversion into tregs","volume":"22","author":"Accogli","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.trim.2026.102385_bb0220","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.immuni.2019.01.020","article-title":"Human FOXP3(+) regulatory t cell heterogeneity and function in autoimmunity and cancer","volume":"50","author":"Wing","year":"2019","journal-title":"IMMUNITY"}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327426000432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327426000432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T06:48:49Z","timestamp":1780296529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327426000432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":43,"alternative-id":["S0966327426000432"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2026.102385","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of SGLT2 inhibition on immune cells and transplant rejection\/failure: A drug-targeted mendelian randomization study","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2026.102385","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102385"}}